Ataraxis AI
Last verified 2026-05-17. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $24.4Mattributed |
|---|---|
| Latest round | seed, $4.0M, 2024-10-01attributed |
| Founded | 2023 |
| Headquarters | New York, USA |
| Industry | healthtech |
| Stage | series-a |
| Website | ataraxis.ai |
Ataraxis AI develops an AI-native platform with clinically validated prognostic and predictive tools for breast cancer. The platform serves oncologists and physicians making treatment decisions. It returns results within 24 hours using multi-modal AI analysis without depleting patient tissue, unlike traditional molecular genomic tests.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-10-01 | seed | $4.0M | undisclosed |
Detected tech stack
Cloudflare, Google Analytics G-?GA4:, jsDelivr, DoubleClick Floodlight, WordPress, PHP, MySQL, jquery 3.5.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $4.0M | attributed | finsmes named as publisher. No document URL on file. |
| Total raised $24.4M | attributed | finsmes named as publisher. No document URL on file. |
| Company existence | self-reported | ataraxis.ai, read 2026-05-17 |
| Description | self-reported | ataraxis.ai, read 2026-05-17 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.